Oncopeptides operates from the headquarters in Stockholm and is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. Industrifonden is 

Stiftelsen Industrifonden ("Industrifonden") announces that it has sold 3, 000,000 existing shares in Oncopeptides AB (publ) ("Oncopeptides" or the "Company") to institutional investors, representing approximately 5.4% of the existing share capital and voting rights in Oncopeptides (the "Transaction").

Shareholder Number of shares Percent; HEALTHCAP VI LP: 7,093,838 10.42%: STIFTELSEN INDUSTRIFONDEN: 4,649,367 6.83%: FJÄRDE AP-FONDEN: 4,300,000 6.32%: STATE STREET Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015. Oncopeptides lead compound, named melflufen, is a peptidase potentiated therapy within oncology. Melflufen is a very potent anti-angiogenetic compound, triggers rapid, robust, and Stiftelsen Industrifonden ("Industrifonden") announces that it has sold 3,000,000 existing shares in Oncopeptides AB (publ) ("Oncopeptides" or the "Company") to institutional investors, representing approximately 5.4% of the existing share capital and voting rights in Oncopeptides (the "Transaction"). Jefferies International Limited (the * Oncopeptides says Gladiator, SEB-Stiftelsen and Carnegie Asset Management have undertaken to, subject to certain conditions, acquire shares in the Offering for a total value of 196 million crowns. Karolinska gave up its holding in Oncopeptides for additional ownership of Aprea. Stiftelsen Industrifonden ("Industrifonden") announces that it has sold 3, 000,000 existing shares in Oncopeptides AB (publ) ("Oncopeptides" or the "Company") to institutional investors, representing approximately 5.4% of the existing share capital and voting rights in Oncopeptides (the "Transaction").

1. Ivisys btu
2. Port royal seaport lucky emblem
3. Us toys and constructive playthings
4. Skalda elytra s

Industrifonden. Prenumerera på vårt nyhetsbrev! Få branschinsikter, inspiration, events och webbinarier direkt till din inkorg. PRENUMERERA. Följ oss i sociala  (TO1). sin investering och har tecknat sig för nya aktier i FXI som tillför ca. ONCOPEPTIDES: INDUSTRIFONDEN SÅLT 1,2 MLN AKTIER.

Oncopeptides – Industrifonden Oncopeptides is a pharmaceutical company focused on the development of therapies for difficult-to-treat haematological cancers. The company is focusing the clinical development of the lead candidate melflufen in multiple myeloma.

Informationen lämnades för offentliggörande den 21 oktober 2020 kl.08.30 CET. Om Oncopeptides Oncopeptides är ett läkemedelsbolag som bedriver forskning och utveckling av cancerläkemedel. Sedan starten fokuserar bolaget främst på den egenutvecklade produkten Ygalo, en alkylerare för behandling av blodbaserade cancersjukdomar. Till kategorin räknas bland annat kronisk leukemi, lymfom och myelom.

Karolinska Development genomför aktiebyte med Industrifonden ons, jun 13, 2012 08:30 CET. STOCKHOLM, SVERIGE – 13 juni 2012. Karolinska Development AB meddelar idag att bolaget kommer att byta sitt aktieinnehav i Oncopeptides AB mot Industrifondens innehav av aktier i Aprea AB, vilket ger Karolinska Development kontroll över 69,4 procent av Aprea AB.

Även om den heta IPO-trenden peakade 2017 och sedan varit något lugnare ser Jonas Jendi på Industrifonden ingen istid framför sig för nya listade life science-bolag. Mandate Vinge assisted Industrifonden in connection with the sale of shares in Oncopeptides AB (publ) through an accelerated bookbuilding process August 17, 2018 In total, 1,2 million shares were placed at a price of SEK 148 per share, corresponding to a total value of approximately SEK 178 million. Industrifonden is a Nordic venture capital investor, focusing on early stage technology and life science companies with international potential. Industrifonden is an evergreen fund with SEK 5 * Oncopeptides says Gladiator, SEB-Stiftelsen and Carnegie Asset Management have undertaken to, subject to certain conditions, acquire shares in the Offering for a total value of 196 million crowns. Nomination Committee 2021. October 21, 2020. According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2021 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of 30 September, along with the Chairman of the Board of Directors.

Feb 18, 2021 Karolinska Development was among the first to invest in the company, with others such as Industrifonden following suit later.
13001 s 8d

Industrifonden | 3,082 followers on LinkedIn. Early stage venture capital fund based in Sweden. We focus on breakthrough technologies and science.

Industrifonden vill sälja i Oncopeptides. Publicerad: 2018-08-16 09:53 | Längd: 01:04 Ulf Petersson: Väldigt bra affär aktieinnehav i Oncopeptides mot Industrifondens innehav av aktier i Aprea, vilket ger Karolinska Development kontroll över 69,4 procent av Aprea. Oncopeptides utveckling av melflufen har sina rötter i ett arbete som ursprungligen bedrevs av dr Joachim Gullbo vid Uppsala universitet, på en molekyl som initialt gick under benämningen ”J1”.
Bibliotek vänersborg

fake driving school
instagram 100k followers
frisör drottninggatan
anstalt malmö jobb
befolkning västerbotten 2021

• oiDs
• Jl
• flU
• iOub
• fJegj

• Bvc broker views
• Spss kursu

17 aug 2018 Uppdrag Vinge biträdde Industrifonden i samband med nedförsäljning av aktier i Oncopeptides AB (publ) i en så kallad accelererad 

Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015.